ER-100 First Patient Dosed: What Partial Epigenetic Reprogramming Means for Longevity Clinics

Partial epigenetic reprogramming has moved from mouse experiments and biotech decks into active first-in-human dosing.

That is important. It is also easy to overstate.

In February 2026, Nature Biotechnology reported that Life Biosciences had received US Food and Drug Administration clearance to begin a Phase 1 trial of ER-100, a gene therapy designed to test partial epigenetic reprogramming in people with serious eye disease.¹ On June 9, 2026, Life Biosciences announced that the first participant had been dosed in that Phase 1 trial.²

That changes the news value. ER-100 is no longer only a permitted study on paper; it is now an active clinical trial in people with optic neuropathies. But patients should understand the difference between first human dosing of an investigational therapy and approval of a longevity treatment.

ER-100 is not available at longevity clinics. It is not a general anti-aging procedure. It is not proof that a clinic can reverse your biological age. It is a regulated, early-stage clinical trial in ophthalmology.

For longevity-clinic buyers, the real lesson is more practical: partial epigenetic reprogramming is one of the most consequential longevity-science signals of 2026, but the credible clinical response today is better education, better diagnostics, cleaner claims, and a refusal to sell “cellular rejuvenation” language as if it were already proven therapy.

What just happened?

Life Biosciences received FDA authorization to proceed with first-in-human studies of ER-100 on January 15, 2026, according to the company’s pipeline page.³ Nature Biotechnology then reported the FDA go-ahead in February.¹ In June, Life Biosciences said the first participant had been dosed.²

The registered study, NCT07290244, is a recruiting Phase 1 trial in open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, with an estimated enrollment of 18 participants.⁴ ClinicalTrials.gov describes ER-100 as an investigational AAV-based epigenetic therapy administered by intravitreal injection to one eye, with systemic doxycycline used for 8 weeks to activate OSK expression.⁴

That distinction matters.

FDA clearance of an investigational new drug application means regulators are allowing a human study to proceed. It does not mean the product is approved. It does not mean the therapy has proven clinical efficacy. And it does not mean patients can buy it from a private longevity clinic.

First dosing is a meaningful step beyond regulatory permission, but it is still the beginning of human testing. Phase 1 trials are primarily about safety, tolerability, dosing, delivery, immune response, and early biological signals. For ER-100, any improvement in visual function or retinal health would be exploratory at this stage, not definitive proof of broad rejuvenation.

What partial epigenetic reprogramming means

Cellular reprogramming began with Shinya Yamanaka’s discovery that adult cells could be induced back toward a pluripotent, stem-cell-like state using transcription factors. The original full reprogramming concept is powerful, but it creates an obvious safety problem: if you erase too much cellular identity, you may create uncontrolled growth, loss of function, or tumor risk.

Partial epigenetic reprogramming tries to do something more subtle. The goal is to reset some age-associated epigenetic patterns while keeping the cell’s identity intact.

In plain English: the aim is not to turn a retinal cell into a stem cell. The aim is to nudge a damaged or aged retinal cell toward a more youthful functional state without making it forget that it is a retinal cell.

That is why OSK — OCT4, SOX2, and KLF4 — matters. ER-100 excludes c-MYC, the fourth Yamanaka factor often associated with uncontrolled growth concerns. ClinicalTrials.gov describes a doxycycline-activated system and local intravitreal delivery to one eye, a design that makes the first human test far narrower than whole-body rejuvenation.⁴

A 2024 review in Ageing Research Reviews describes partial reprogramming as a strategy that may reset aging-associated epigenetic marks without erasing cellular identity, while emphasizing that the field is still emerging and raises scientific, safety, ethical, and socioeconomic questions.⁵

That is the right frame: promising biology, high uncertainty, and real safety questions.

Why the first human trial is in eye disease

The eye is a logical starting point for partial reprogramming.

It is relatively accessible. It allows local delivery. Clinicians can measure structure and function using established ophthalmology tools. And diseases such as glaucoma and ischemic optic neuropathy involve damaged retinal or optic-nerve biology where restoring function is a concrete clinical goal.

This is very different from claiming whole-body rejuvenation.

A localized eye trial lets researchers test delivery, safety, immune response, biodistribution, gene-expression control, and early functional signals in a defined tissue. It does not answer whether partial reprogramming can safely affect the brain, liver, muscle, vasculature, immune system, or entire body.

The scientific backstory is real. A 2020 Nature paper reported that in mouse models, expression of reprogramming factors could help recover youthful epigenetic information and restore vision-related function.⁶ But animal models are not clinical proof. The point of ER-100 entering human dosing is precisely that the field now needs human safety and efficacy data.

Why this matters for longevity clinics

Partial epigenetic reprogramming matters to longevity clinics because it changes the horizon of what may eventually become medicine.

Today, most longevity clinics operate in one of three zones:

1. Preventive medicine and diagnostics — blood markers, imaging, cardiometabolic risk, sleep, exercise, body composition, cancer screening, and physician review.
2. Optimization and lifestyle medicine — nutrition, resistance training, recovery, metabolic health, hormone review, and behavior change.
3. Frontier interventions — regenerative claims, biological-age claims, peptides, plasmapheresis, stem-cell products, and sometimes speculative anti-aging protocols.

Partial reprogramming belongs in a fourth zone: regulated biotech therapeutics for age-related disease. That zone is not the same as spa medicine, wellness optimization, or executive diagnostics.

Clinic claim category	Where it fits today	What a buyer can reasonably expect	What would be misleading
Preventive diagnostics	Current longevity-clinic practice	Labs, imaging, cardiometabolic risk review, physician interpretation, and follow-up planning	Presenting measurement as biological age reversal
Optimization and lifestyle medicine	Current clinical or coaching practice	Nutrition, exercise, sleep, recovery, metabolic care, and medically indicated hormone review	Describing lifestyle response as cellular reprogramming
Frontier interventions	Experimental, off-label, or jurisdiction-dependent care	Careful evidence review, consent, adverse-event tracking, and clear regulatory status	Borrowing Yamanaka-factor or ER-100 language for unrelated therapies
Partial epigenetic reprogramming	Regulated biotech therapeutics and clinical trials	Education, trial literacy, and referral to legitimate research pathways when relevant	Selling commercial “age reversal,” “epigenetic restoration,” or “cellular rejuvenation” outside a regulated trial

A serious clinic can discuss partial reprogramming as part of patient education. It can help patients understand what “FDA clearance to test” means. It can explain why a disease-specific trial is not the same as a consumer treatment. It can help patients avoid misleading claims.

What it should not do is imply that current biological-age testing, supplements, peptides, NAD+ IVs, stem cells, or “cellular rejuvenation packages” are equivalent to partial epigenetic reprogramming.

If you are evaluating a clinic today, the strongest current offerings are still more conventional: comprehensive assessment, preventive cardiology, metabolic health, cancer-risk screening when appropriate, sleep and fitness assessment, evidence-aware imaging, and longitudinal follow-up. Start with what the clinic can do now, not what biotech might do later.

Our guide to what a longevity health assessment should include is a better booking checklist than any claim about future reprogramming therapies.

The safety questions are the story

The biggest question in partial reprogramming is not whether cells can be made to look younger in a lab. The question is whether that biology can be controlled safely in humans.

Key safety questions include:

• Cell identity: Can cells retain their function after partial reprogramming?
• Cancer risk: Can expression be controlled tightly enough to avoid unwanted proliferation?
• Delivery: Which vector, tissue, dose, and delivery route are safe?
• Reversibility: Can the signal be paused, stopped, or reversed if needed?
• Immune response: Will the vector or expressed factors trigger harmful inflammation?
• Durability: Does any benefit last, and does repeated dosing create new risks?
• Off-target effects: What happens outside the intended tissue?

These are not theoretical concerns. They are why a Phase 1 trial starts with safety and tolerability. They are also why clinic marketing should be conservative.

Biological age is not one switch. Epigenetic clocks, methylation patterns, tissue repair, immune function, cancer risk, mitochondrial function, proteostasis, senescence, and organ-specific decline do not move as one simple dashboard score.

This is where consumers should be especially careful. A clinic that claims to “reverse biological age” because a blood-based epigenetic test changed is making a weaker claim than it may sound. A clock movement is not the same as clinical rejuvenation, functional recovery, reduced mortality, or a proven disease benefit.

For that distinction, read our guide to biological-age testing technologies in longevity clinics and our review of epigenetic clock accuracy.

How clinics may misuse the story

Expect to see “cellular rejuvenation” language spread faster than the medicine.

That is the predictable risk. When a legitimate biotech milestone enters the news cycle, some clinics will borrow the vocabulary and attach it to unrelated services.

Red-flag claims include:

• “We offer epigenetic reprogramming” without a regulated trial or approved product.
• “FDA-cleared age reversal” when the actual clearance is for a Phase 1 study and the current milestone is first participant dosing.
• “Yamanaka-factor inspired rejuvenation” attached to supplements, peptides, exosomes, or IV therapies.
• “Epigenetic age reversal guaranteed” based on a commercial biological-age test.
• “Cellular rejuvenation therapy” without naming the active product, regulator, protocol, risks, and evidence.

This does not mean every clinic discussing epigenetics is suspect. It means claims should be precise.

A credible clinic can say: “Partial epigenetic reprogramming is entering early human testing for eye disease. It is not currently available as a general longevity therapy. We monitor the field and focus today on validated preventive care.”

A less credible clinic says: “This proves rejuvenation medicine is here — book our cellular age-reversal package.”

The difference is not subtle.

What a serious clinic should do now

For now, a serious longevity clinic should treat partial epigenetic reprogramming as a research milestone, not a treatment menu item.

It should:

• Explain the difference between FDA clearance for a trial and FDA approval of a therapy.
• Explain the difference between permission to test, first patient dosed, recruiting status, trial completion, and approval.
• Avoid implying ER-100 or similar approaches are available commercially.
• Separate epigenetic-clock testing from therapeutic reprogramming.
• Discuss the limits of blood-based biological-age tests.
• Focus on evidence-based prevention while monitoring clinical-trial outcomes.
• Refer eligible patients to legitimate trial registries or academic centers when appropriate.
• Avoid selling unrelated interventions using reprogramming terminology.

This is the broader standard we argue for in our guide to longevity clinic standards for diagnostics, AI, and biomarkers: frontier science should raise the standard of interpretation, not lower the bar for claims.

Other clinics worth considering

If your interest in partial reprogramming comes from a serious desire to understand your current risk profile, you do not need a clinic claiming to reprogram cells. You need a clinic that can build a high-quality baseline and interpret it responsibly.

Human Longevity Inc. is worth considering for advanced diagnostics: genomics, imaging, biomarkers, and physician-led interpretation. It is not a partial-reprogramming provider, but it fits patients who want data-rich preventive assessment.

Biograph is another diagnostics-first model for people interested in a more technology-forward health assessment. The buyer question is not whether it offers “rejuvenation,” but whether its imaging, biomarkers, and follow-up lead to useful decisions.

Clinique La Prairie and Lanserhof sit closer to the premium European longevity and medical-wellness tradition. They may be relevant if you want physician-supervised prevention, recovery, diagnostics, and lifestyle medicine — but any “cellular rejuvenation” language should still be interrogated carefully.

Use the clinic directory, WLC rankings, compare tool, and find-your-clinic flow to separate diagnostics, medical governance, price, location, and treatment claims.

Buyer checklist: questions to ask about cellular rejuvenation, age reversal, epigenetic restoration, or ER-100

Before paying any clinic that uses reprogramming, epigenetic, cellular-rejuvenation, age-reversal, or ER-100-adjacent language, ask:

1. What exact intervention are you offering? Name the product, device, test, or protocol.
2. Is it approved, investigational, off-label, or wellness-only? Do not accept vague answers.
3. Which regulator oversees it? FDA, EMA, MHRA, Swissmedic, a national medicines agency, or no therapeutic regulator?
4. Is this related to ER-100 or partial reprogramming, or just inspired marketing language?
5. What human clinical evidence exists? Disease trial, safety trial, biomarker study, animal data, or theory?
6. What are the known risks? Immune reactions, cancer risk, delivery risk, ocular risk, off-target effects, or unknowns?
7. How do you measure benefit? Symptoms, functional outcomes, imaging, tissue markers, or only a commercial epigenetic clock?
8. What happens if results worsen? Who follows up medically?
9. Can I share the protocol with my primary physician or specialist? Serious clinics should welcome external review.
10. Are you selling a therapy or educating me about emerging science? Those are different services.

If a clinic cannot answer those questions, do not buy the promise.

FAQ

Is partial epigenetic reprogramming the same as age reversal?

No. Partial epigenetic reprogramming aims to reset some age-associated cellular marks while preserving cell identity. That is not the same as proving whole-body age reversal in humans. ER-100 first participant dosing is a milestone, but the study is still disease-specific, early-stage, and safety-focused.

Is ER-100 available at longevity clinics?

No. ER-100 is an investigational gene therapy in Phase 1 clinical testing for serious eye disease. It is not an approved consumer longevity therapy, and clinics should not imply that patients can buy it as an anti-aging treatment.

Are epigenetic clocks the same as epigenetic reprogramming?

No. Epigenetic clocks are measurement tools. They estimate biological age from methylation patterns. Epigenetic reprogramming is an intervention strategy designed to alter cellular state. A changed clock result does not prove clinical rejuvenation.

Can a clinic reprogram my cells today?

A credible clinic should not claim to offer partial epigenetic reprogramming today unless it is part of a properly regulated trial. Clinics may discuss the science, interpret biological-age tests cautiously, and help patients follow legitimate research — but they should not sell reprogramming as an available longevity service.

Bottom line

Partial epigenetic reprogramming entering active human dosing is a real milestone. It may become one of the most important categories in age-related disease medicine.

But the current milestone is not consumer age reversal. It is not a longevity-clinic treatment. It is not an invitation for clinics to relabel peptides, exosomes, supplements, or biological-age tests as cellular rejuvenation.

The best longevity clinics in 2026 should be excited by the science and strict about the claims. They should explain what is real, what is investigational, and what is not available. That standard matters because the next decade of longevity medicine will depend not only on better biology, but on whether clinics can translate it without turning it into hype.

Footnotes

1. FDA go-ahead to test cellular rejuvenation therapy in humans, Nature Biotechnology, 2026. ↩ ↩²

2. Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies, Life Biosciences, 2026. ↩ ↩²

3. Pipeline: First-ever Clinical Study of Epigenetic Restoration, Life Biosciences. ↩

4. Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy, ClinicalTrials.gov, NCT07290244. ↩ ↩² ↩³

5. Epigenetic reprogramming as a key to reverse ageing and increase longevity, Ageing Research Reviews, 2024. ↩

6. Reprogramming to recover youthful epigenetic information and restore vision, Nature, 2020. ↩